Rosacea treatment: what works for redness, bumps and flushing

The most effective rosacea treatment depends on which features you have: bumps and pustules respond best to anti-inflammatory creams such as ivermectin or azelaic acid, persistent redness to short-acting vasoconstrictor gels, and visible blood vessels to laser or intense pulsed light. Most people need a combination, plus gentle skincare and sun protection, and many need some form of maintenance once the skin is calm.

Rosacea is a long-term condition. Treatment can bring it under good control, often to clear or almost clear skin, but flares can return when treatment stops. That is why dermatologists now plan care around the features you actually see in the mirror rather than around a single label.

This guide walks through that approach, what each option targets, how long it usually takes, and where an in-person dermatologist fits in.

Key takeaways

- Rosacea is now treated by phenotype: each feature (redness, bumps, flushing, vessels, thickened skin, eyes) gets its own targeted option [1][2].

- For bumps and pustules, azelaic acid and ivermectin have high-certainty evidence; metronidazole has moderate-certainty evidence [5].

- Brimonidine and oxymetazoline reduce redness for several hours, but they do not shrink visible vessels; laser and light therapies target those [5].

- Expect weeks, not days: most trials measure results at 12 to 16 weeks, and relapse after stopping is common [6][7].

- Oral options such as low-dose doxycycline or low-dose isotretinoin are for a dermatologist to manage in person.

From subtypes to phenotypes: why the label matters less now

For years, rosacea was sorted into four subtypes (erythematotelangiectatic, papulopustular, phymatous and ocular). The problem is that most people do not fit neatly into one box. Someone can have persistent redness, a few bumps on the cheeks and gritty eyes all at once.

In 2017 the global ROSacea COnsensus (ROSCO) panel recommended moving to a phenotype-led approach [1]. Under this scheme, two features are considered diagnostic on their own:

• persistent redness in the centre of the face that periodically intensifies;
• phymatous changes, meaning thickened skin, most often on the nose.

Flushing, visible blood vessels (telangiectasia), papules and pustules, and eye symptoms are "major" features that support the diagnosis but are not diagnostic by themselves [1]. The 2019 ROSCO update confirmed this shift, recommended combination therapy for people with several features, and set complete clearance as the main goal of treatment [3].

In practice, this means your treatment plan is built feature by feature. Our overview of rosacea and how it is assessed covers the basics if you are just starting out.

What each treatment targets

The best evidence comes from two large reviews by van Zuuren and colleagues. The 2015 Cochrane review pooled 106 randomised trials with 13,631 participants [4], and the 2019 update grew to 152 studies with 20,944 participants, organised by phenotype [5]. The table below summarises what they found.

Feature	Options with the best evidence	Certainty of evidence	Who manages it
Papules and pustules	Azelaic acid cream or gel, ivermectin cream	High [5]	Topicals can be assessed online
Papules and pustules	Metronidazole cream or gel	Moderate [5]	Topicals can be assessed online
Papules and pustules (moderate to severe)	Doxycycline 40 mg modified release, isotretinoin	Moderate to high [5]	Dermatologist in person
Persistent redness	Brimonidine gel	High [5]	Topical, doctor assesses
Persistent redness	Oxymetazoline cream	Moderate [5]	Topical, doctor assesses
Visible vessels and redness	Pulsed dye laser, intense pulsed light	Low to moderate [5]	Dermatologist in person
Eye symptoms	Lid hygiene, artificial tears, referral	Variable [2][5]	A doctor assesses eye symptoms; ophthalmology referral as advised [2]

Bumps and pustules (papulopustular features)

This is where topical treatment has the strongest track record.

• Azelaic acid reduces inflammation and has high-certainty evidence for papules and pustules [5]. In the Cochrane review, pooled data from four trials showed it was more effective than placebo on participants' own assessments [4]. Our guide to azelaic acid for rosacea and the broader azelaic acid skin guide explain how it is used and what tingling to expect.
• Ivermectin 1% cream is a once-daily anti-inflammatory option with high-certainty evidence [5]. In a 962-person trial, once-daily ivermectin reduced inflammatory lesions by 83.0% at week 16, compared with 73.7% for twice-daily metronidazole, and 84.9% versus 75.4% of patients were rated clear or almost clear [6]. The difference started to show from week 3.
• Metronidazole has moderate-certainty evidence and remains a reasonable, well-tolerated option [5].

If you mainly have bumps, our papulopustular rosacea guide explains how these options are usually set up.

Persistent redness

Redness that never fully fades is often the most frustrating feature, and it responds differently from bumps.

• Brimonidine gel narrows small blood vessels. In two pivotal trials it reduced redness significantly more than a placebo gel, with a difference seen as early as 30 minutes after the first application and lasting through 12 hours [8].
• Oxymetazoline cream works in a similar way and has moderate-certainty evidence [5].

Both are temporary: the effect lasts hours, then the redness returns until the next application [5][8]. They do not remove visible vessels, and a doctor usually suggests starting on a small area to see how your skin responds. Read more in our guide to persistent rosacea redness.

Flushing and triggers

Transient flushing is hard to treat with any single product. Persistent redness can intensify in response to triggers [3], and ROSCO lists general skincare and trigger avoidance as part of the plan to discuss with every patient [2][3]. Common personal triggers include heat, alcohol, spicy food, hot drinks, strong sun and stress, but they vary from person to person. We look at what the research actually shows about each trigger in rosacea triggers: what the evidence says.

Visible blood vessels and thickened skin

For telangiectasia, procedures lead the evidence: pulsed dye laser and intense pulsed light have low-to-moderate certainty evidence for redness and especially for visible vessels [5], and the Cochrane review found pulsed dye laser and intense pulsed light appeared similarly effective in the one comparison available [4]. Thickened skin (phyma), caused by fibrosis and enlarged oil glands, most often on the nose [3], is a feature for which ROSCO sets out separate first-line options [2]; it is managed by a dermatologist in person.

Oral options a dermatologist may use in person

When bumps are moderate to severe, widespread or do not respond to creams, a dermatologist may add an oral option. These need an in-person assessment and follow-up.

• Doxycycline 40 mg modified release is an anti-inflammatory dose rather than a classic antibiotic dose. In two 16-week trials, inflammatory lesions fell by 11.8 and 9.5 on average (from about 20) versus 5.9 and 4.3 with placebo [9]. It is contraindicated in the second and third trimesters of pregnancy, prolonged use is not recommended while breastfeeding, and it can cause sun sensitivity [12].
• Low-dose isotretinoin is reserved for difficult cases. In a 156-person trial, 57.4% of people on 0.25 mg/kg/day reached at least a 90% reduction in bumps after four months, compared with 10.4% on placebo [10]. However, 58.3% of those followed afterwards relapsed, with a median of 15 weeks [10]. Isotretinoin causes serious birth defects and requires a strict pregnancy prevention programme with effective contraception from one month before until one month after treatment [13].

These are not medicines to start without close medical supervision. Hi Doctor does not prescribe them: for oral treatment, see a dermatologist in person.

Realistic timelines

Rosacea treatment is slower than most people expect. A rough guide based on the trials:

1. Redness gels: visible effect within 30 minutes of application, lasting several hours [8].
2. Topicals for bumps: early changes from around 3 weeks; trials judge results at 12 to 16 weeks [4][6].
3. Oral doxycycline: improvement was still continuing at 16 weeks, with no plateau [9].
4. Low-dose isotretinoin: results assessed after 4 months [10].
5. Laser or light: usually several sessions, planned by the dermatologist.

ROSCO advises that if treatment is not enough after an appropriate duration, the next step is either switching to another first-line option or adding one [2]. Give a cream a fair trial before deciding it does not work.

Combining treatments

Because most people have more than one feature, combination therapy is the norm rather than the exception. ROSCO states that several features can be treated at the same time with several agents, for example a cream for bumps plus a redness gel, or a topical plus laser [2][3].

A few practical points:

• Introduce one new product at a time, so you know what causes irritation if it happens.
• Keep the rest of your routine simple: a gentle cleanser, a fragrance-free moisturiser and daily broad-spectrum sunscreen.
• Avoid scrubs, alcohol-based toners and over-the-counter acids alongside prescription treatment unless a doctor agrees.

Maintenance: keeping rosacea calm

Rosacea is controlled, not eliminated. In the ATTRACT extension study, people whose skin cleared were followed for 36 weeks after stopping treatment. Relapse occurred in 62.7% of those who had used ivermectin and 68.4% of those who had used metronidazole, with a median time to first relapse of 115 versus 85 days [7].

This is why ROSCO says maintenance depends on the treatment used and on your preferences [2], and why ongoing monitoring and dialogue between doctor and patient are recommended [3]. Common strategies include continuing a topical a few times a week, restarting promptly at the first sign of a flare, and keeping trigger control and sun protection going all year.

Safety and pregnancy

Topicals are generally well tolerated, but there are limits.

• Ivermectin cream is a prescription-only medicine in Spain and is not recommended during pregnancy; during breastfeeding, the decision weighs benefit against an unexcluded risk to the infant [11].
• Oral doxycycline and isotretinoin carry the pregnancy restrictions described above [12][13].
• Irritation: in trials, side effects of rosacea treatments were mostly mild and transient [4], but stinging or dryness can occur at the start, for example with azelaic acid. Tell your doctor if it does not settle.
• Sun: sunlight is a common trigger, and oral doxycycline can increase sun sensitivity [12]. Daily sunscreen helps on both counts.

Whatever you use, a doctor reviews your history, medicines and pregnancy plans, then decides whether a given treatment is appropriate for you.

When to see a doctor

See a doctor promptly, and a dermatologist in person where indicated, if:

• your eyes are red, painful, sensitive to light or your vision changes; eye symptoms need a doctor, who may refer you to an ophthalmologist [2];
• the skin on your nose or face is thickening;
• bumps are widespread, painful or not improving after a full course of topical treatment;
• you are pregnant, planning pregnancy or breastfeeding and need treatment;
• you are unsure it is rosacea at all: acne, seborrhoeic dermatitis, lupus and steroid-induced rashes can look similar.

If you'd like a doctor to look at your case, Hi Doctor offers an online consultation with a doctor licensed in Spain, who replies in under 2 hours on average. Skin treatments are topical only. If a prescription is appropriate it is issued in Spain, and each pharmacy decides whether to dispense it; if the doctor declines, your consultation fee is refunded in full. See how it works.

Sources

1. Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431-438. doi:10.1111/bjd.15122. https://pubmed.ncbi.nlm.nih.gov/27718519/
2. Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465-471. doi:10.1111/bjd.15173. https://pubmed.ncbi.nlm.nih.gov/27861741/
3. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269-1276. doi:10.1111/bjd.18420. https://pubmed.ncbi.nlm.nih.gov/31392722/
4. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;(4):CD003262. doi:10.1002/14651858.CD003262.pub5. https://pubmed.ncbi.nlm.nih.gov/25919144/
5. van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65-79. doi:10.1111/bjd.17590. https://pubmed.ncbi.nlm.nih.gov/30585305/
6. Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103-1110. doi:10.1111/bjd.13408. https://pubmed.ncbi.nlm.nih.gov/25228137/
7. Taieb A, Khemis A, Ruzicka T, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829-836. doi:10.1111/jdv.13537. https://pubmed.ncbi.nlm.nih.gov/26691278/
8. Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650-656. https://pubmed.ncbi.nlm.nih.gov/23839181/
9. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802. doi:10.1016/j.jaad.2006.11.021. https://pubmed.ncbi.nlm.nih.gov/17367893/
10. Sbidian E, Vicaut E, Chidiack H, et al. A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol. 2016;136(6):1124-1129. doi:10.1016/j.jid.2016.01.025. https://pubmed.ncbi.nlm.nih.gov/26854486/
11. AEMPS, CIMA. Ivermectin 10 mg/g cream: summary of product characteristics (ficha técnica), registration no. 79911, section 4.6. https://cima.aemps.es/cima/pdfs/ft/79911/FT_79911.pdf
12. AEMPS, CIMA. Doxycycline 40 mg modified-release hard capsules: summary of product characteristics (ficha técnica), registration no. 73622, sections 4.3, 4.4 and 4.6. https://cima.aemps.es/cima/pdfs/ft/73622/FT_73622.pdf
13. AEMPS, CIMA. Isotretinoin 40 mg soft capsules: summary of product characteristics (ficha técnica), registration no. 76045, sections 4.3 and 4.4. https://cima.aemps.es/cima/pdfs/ft/76045/FT_76045.pdf